2 results
Contributors
-
- By Sonia Ancoli-Israel, Ragnar Asplund, Michel Billiard, Theresa M. Buckley, Rohit Budhiraja, Robert N. Butler, Daniel J. Buysse, Scott S. Campbell, Daniel P. Cardinali, Julie Carrier, Cynthia L. Comella, Jana R. Cooke, Pietro Cortelli, Agnès Demazieres, Glenna A. Dowling, Luigi Ferini-Strambi, Philip R. Gehrman, Nalaka Sudheera Gooneratne, David S. Hallegua, Patrick J. Hanly, David G. Harper, Orla P. Hornung, Magdolna Hornyak, Michal Karasek, Milton Kramer, Andrew D. Krystal, Malcolm H. Lader, Rachel Leproult, Kenneth L. Lichstein, Andrea H.S. Loewen, Rémy Luthringer, Laurin J. Mack, Evelyn Mai, Atul Malhotra, Jennifer L. Martin, Judy Mastick, Monique A.J. Mets, Andrew A. Monjan, Timothy H. Monk, Daniel Monti, Jaime M. Monti, Patricia J. Murphy, C. Ineke Neutel, Eric A. Nofzinger, Seithikurippu R. Pandi-Perumal, Scott B. Patton, Donald B. Penzien, Max H. Pittler, Giora Pillar, Marc J. Poulin, Louis J. Ptácek, Stuart F. Quan, Jeanetta C. Rains, Megan E. Ruiter, Bruce D. Rybarczyk, Colin M. Shapiro, Vijay Kumar Sharma, D. Warren Spence, Kai Spiegelhalder, Luc Staner, Stephanie A. Studenski, Nikola N. Trajanovic, Eve Van Cauter, Gregory S. Vander Wal, Joris C. Verster, Aleksandar Videnovic, Matthew P. Walker, Daniel J. Wallace, David K. Welsh, David P. White, Barbara Wider, Theresa B. Young, Stefano Zanigni
- Edited by S. R. Pandi-Perumal, Jaime M. Monti, Universidad de la República, Uruguay, Andrew A. Monjan, National Institute on Aging, Bethesda, Maryland
-
- Book:
- Principles and Practice of Geriatric Sleep Medicine
- Published online:
- 04 August 2010
- Print publication:
- 26 November 2009, pp ix-xii
-
- Chapter
- Export citation
7 - Automated design and high throughput chemical synthesis of siRNA
-
- By Yerramilli V. B. K. Subrahmanyam, QIAGEN, Inc., Eric Lader, QIAGEN, Inc.
- Edited by Krishnarao Appasani, GeneExpression Systems, Inc., Massachusetts
- Foreword by Andrew Fire, Stanford University, California, Marshall Nirenberg
-
- Book:
- RNA Interference Technology
- Published online:
- 31 July 2009
- Print publication:
- 17 January 2005, pp 118-128
-
- Chapter
- Export citation
-
Summary
Introduction
The application of RNA interference (RNAi) to mammalian cells (Caplen et al., 2001; Elbashir et al., 2001a) has the potential to revolutionize the field of functional genomics and target validation in drug discovery research (Harborth et al., 2001; Tuschl and Borkhardt, 2002). In addition RNAi is also viewed as potential means for nucleic acid-based therapeutic applications. The ability to simply, effectively, and specifically down-regulate the expression of genes in mammalian cells holds enormous scientific, commercial, and therapeutic potential. To ensure success in gene silencing experiments, the design and synthesis of the targeting molecule (the siRNA) must be carefully optimized. The present chapter describes the design criteria for successful gene silencing, followed by a description of recent improvements in high-throughput chemical synthesis of siRNAs, and transcriptome wide gene silencing studies.
Advantages of using RNAi over other technologies for functional genomics
A variety of methods and technologies are available for studying gene function such as gene knockouts and transgenic animal models (Capecchi, 1989; Feil et al., 1996; Jaenisch, 1998; Le and Sauer, 2001; Perkins, 2002), the majority of which are time-consuming and expensive. To facilitate functional genomics in mammalian cells at a transcriptome-wide level, an efficient approach that enables rapid and high throughput analysis is required. Use of synthetic siRNA for RNA interference offers a rapid and cost-effective alternative to previous methods, and can be used to silence expression of several genes simultaneously (Harborth et al., 2001; Kamath et al., 2003; Kamath and Ahringer, 2003).